Paper Details

  1. Home
  2. Paper Details

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Author: AppelbaumFrederick R, ByrdJohn C, ChangJulie E, CoubanStephen, FehnigerTodd A, GodwinJohn E, HalvorsonAlese E, HeeremaNyla A, HokeEva, LarsonRichard A, MandrekarSumithra J, RobinsonSue, RuppertAmy S, SmithMitchell R, StoneRichard M, TallmanMartin S, ThirmanMichael J

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2 study compared the effectiveness of three chemoimmunotherapy regimens (fludarabine plus rituximab [FR], FR plus lenalidomide consolidation [FR+L], and FR plus cyclophosphamide [FCR]) for untreated patients with non-del(11q) chronic lymphocytic leukemia (CLL), highlighting the potential for lenalidomide in improving outcomes.
Paper Details　
Original Abstract of the Article :
Prior to novel targeted agents for chronic lymphocytic leukemia (CLL), the best chemoimmunotherapy regimen in patients with non-del(11q) disease was unclear. The role of lenalidomide was also not defined. This phase 2 study randomized 342 untreated patients with non-del(11q) CLL requiring therapy to...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058242/

データ提供：米国国立医学図書館（NLM）

Lenalidomide: A New Ally in the Fight Against CLL

This study delves into the world of chronic lymphocytic leukemia (CLL), a type of blood cancer, and explores the role of lenalidomide in combination with chemoimmunotherapy. Think of CLL as a stubborn sandstorm that relentlessly challenges a camel caravan's journey. The researchers investigated the effectiveness of adding lenalidomide to the standard fludarabine plus rituximab (FR) regimen, comparing it to FR alone and FR plus cyclophosphamide (FCR). The results showed that adding lenalidomide to the chemoimmunotherapy regimen significantly improved progression-free survival (PFS) compared to FR alone.

Lenalidomide's Promise: Extending PFS

The study revealed that lenalidomide consolidation after chemoimmunotherapy significantly improved PFS in patients with CLL, offering a potential strategy for extending the time before disease progression. This is like a camel caravan using a more durable camel saddle (lenalidomide) to withstand the rigors of the desert journey, allowing them to travel further before needing a rest.

Hope for CLL Patients: A Continued Pursuit

This research highlights the potential benefits of lenalidomide in the treatment of CLL, offering hope for a more effective and durable response. This is a significant step forward in the fight against this challenging disease, like a camel caravan finding a new oasis that provides sustenance and allows them to continue their journey. The study encourages further research to investigate the optimal use of lenalidomide in CLL treatment, aiming to improve patient outcomes and enhance their quality of life.

Dr.Camel's Conclusion

This study reveals the potential of lenalidomide in improving the treatment of CLL, offering a new weapon in the fight against this challenging disease. By extending PFS, lenalidomide provides a more durable response, allowing patients to navigate their journey with greater resilience. This is like a camel caravan finding a new oasis that provides sustenance and allows them to continue their journey. The study underscores the importance of ongoing research to optimize the use of lenalidomide in CLL treatment, aiming to improve patient outcomes and enhance their quality of life.

Date :
  1. Date Completed 2019-04-03
  2. Date Revised 2020-07-24
Further Info :

Pubmed ID

30030269

DOI: Digital Object Identifier

PMC6058242

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.